Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3398752 | Clinical Microbiology and Infection | 2008 | 4 Pages |
Abstract
ABSTRACTSulbactam irreversibly inhibits the hydrolytic activity of β-lactamases. This compound is commercially available in combination with either ampicillin or cefoperazone. In each instance, the activity of the partner antibiotic against β-lactamase-producing bacteria is restored. One of the particular advantages of using sulbactam-containing combinations is that sulbactam itself has inherent activity against some Acinetobacter baumannii. Sulbactam combinations have not demonstrated strong selective pressures for extended-spectrum β-lactamase-producing Enterobacteriaceae and vancomycin-resistant enterococci. In contrast to clavulanate, sulbactam does not induce class I (Ampc) chromosomal β-lactamases in Enterobacteriaceae.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
M. Akova,